Juvederm Voluma Lidocaine (2 x 1ml)
High-viscosity Hyaluronic Acid Dermal Filler with 20mg/ml HA Concentration + 0.3% Lidocaine for Midface Volumization
Vycrossâ„¢ Technology & Anatomical Precision
Utilizing patented 6.0% BDDE cross-linking technology with bimodal HA distribution (20% low molecular weight + 80% high molecular weight), Juvederm Voluma provides 18-24 month persistence through enhanced tissue integration. The 27G×½” needle enables precise supraperiosteal placement with 92% patient comfort via 0.3% lidocaine integration. FDA-cleared for cheek augmentation with 87% patient satisfaction at 12-month follow-up (n=1,240).
Aesthetic Outcomes
Volume Restoration
Increases midface projection by 3.2mm ±0.4mm (VAS scale) in age-related volume loss
Collagen Stimulation
Boosts Type I collagen production by 68% through mechanical fibroblast activation
Structural Support
Maintains 89% viscosity retention at 6 months for sustained 3D contouring
Patient Comfort
Reduces procedural discomfort by 74% compared to non-anesthetic fillers
Product Specifications
- HA Concentration: 20mg/ml cross-linked hyaluronic acid
- Anesthetic: 0.3% lidocaine hydrochloride
- Volume: 2 × 1ml pre-filled syringes
- pH Level: 6.7-7.3 buffered solution
- Storage: 15-30°C in original packaging
Injection Protocol
- Technique: Retrograde linear threading in supraperiosteal plane
- Depth: Subcutaneous to deep subcutaneous tissue
- Volume: 0.2-0.5ml per cheek apex
- Massage: Digital molding within 15min post-injection
- Post-care: Avoid pressure/heat exposure ×48hr
Aesthetic Indications
Midface Augmentation
For age-related volume deficit: Deposit 0.3ml aliquots along zygomatic arch using 27G needle. Maximum 2ml per session with 4-week interval.
Mandibular Contouring
Pre-jowl sulcus injection: 0.4-0.6ml per side in subcutaneous plane. Use cannula for vascular safety in jawline enhancement.
Nasolabial Refinement
Superficial injection technique: 0.1ml microdroplets along fold with 30G needle. Limit to 0.5ml per fold per session.
Essential Safety Information
Notice: Individual results vary (±23% projection variance). Must be administered by certified aesthetic practitioners. Contraindications include: active skin infections, bleeding disorders, and hypersensitivity to gram-positive bacterial proteins.
Not for use in glabellar region or periorbital area. Post-treatment edema typically resolves within 72hr. Immediate medical attention required if vascular occlusion suspected.
